TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6123281

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 31309815

Group type: EXPERIMENTAL
Intervention: Dumbbell weight 0.48 kg, shoulder flexion 150°/elbow 180°
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dumbbell weight 0.48 kg, shoulder flexion 120°/elbow 150°
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dumbbell weight 0.48 kg, shoulder flexion 90°/elbow 120°
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dumbbell weight 0.48 kg, shoulder flexion 60°/elbow 90°
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dumbbell weight 0.75 kg, shoulder flexion 150°/elbow 180°
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dumbbell weight 0.75 kg, shoulder flexion 120°/elbow 150°
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dumbbell weight 0.75 kg, shoulder flexion 90°/elbow 120°
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dumbbell weight 0.75 kg, shoulder flexion 60°/elbow 90°
Number of subjects: 15
Study: 28655715

Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BLSA Obese Group
Number of subjects: 60

Group type: COMPARATOR
Intervention: BLSA Lean Group
Number of subjects: 60
Study: 24590990

Group type: EXPERIMENTAL
Intervention: Drainage
Number of subjects: 168

Group type: COMPARATOR
Intervention: Non-drainage
Number of subjects: 168
Study: 23092595

Group type: EXPERIMENTAL
Intervention: DVD-based training program for informal caregivers
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 29
Study: 19444870

Group type: EXPERIMENTAL
Intervention: Moderate-intensity lifestyle intervention
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Low-intensity lifestyle intervention
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Physical activity increase to > or =150 minutes/week
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Objective measure of fitness
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Physical activity above 60 minutes/week
Number of subjects: 141
Study: 17878794

Group type: EXPERIMENTAL
Intervention: Soft lullaby music
Number of subjects: 69

Group type: COMPARATOR
Intervention: No music
Number of subjects: 69
Study: 14693576

Group type: EXPERIMENTAL
Intervention: 250 mg/kg FDP IV before surgery and 2.5 mM FDP as a cardioplegic additive (n = 15)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: FDP treatment across all regimens (n = 88; 44 FDP, 44 control)
Number of subjects: 120
Study: 11836046

Group type: EXPERIMENTAL
Intervention: Calcium carbonate 625 mg (250 mg elemental calcium) three times a day (group A)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Calcium carbonate 625 mg (250 mg elemental calcium) plus 0.625 mg/day of conjugated equine estrogen and 5 mg medrogestone acetate (group B)
Number of subjects: 56
Study: 10071455

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control (flomoxef sodium and tobramycin without G-CSF)
Number of subjects: 214
Study: 8530843

Group type: EXPERIMENTAL
Intervention: Warm group (Calafiore technique)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cold group (traditional technique)
Number of subjects: 20
Study: 2247106

Group type: EXPERIMENTAL
Intervention: A‐64077 (5‐lipoxygenase inhibitor)
Number of subjects: 13
Study: 7443930

Group type: EXPERIMENTAL
Intervention: Frontalis EMG biofeedback
Number of subjects: 24

Group type: COMPARATOR
Intervention: No-feedback (instructions only)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Adaptation control condition
Number of subjects: 24
Study: 30578758

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived mesenchymal stem cell transplantation (MSCT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Allogeneic cultivated limbal epithelial transplantation (CLET)
Number of subjects: 28
Study: 24464327

Group type: EXPERIMENTAL
Intervention: Omega‐3/6 fatty acids (Equazen eye q™)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined MPH + Omega‐3/6
Number of subjects: 90

Group type: COMPARATOR
Intervention: Omega‐3/6
Number of subjects: 90

Group type: COMPARATOR
Intervention: Methylphenidate (MPH) alone
Number of subjects: 90
Study: 25770987

Group type: EXPERIMENTAL
Intervention: Heparin-bonded grafts
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard grafts
Number of subjects: 160
Study: 23406190

Group type: EXPERIMENTAL
Intervention: RYGB (Laparoscopic Roux-en-Y Gastric Bypass)
Number of subjects: 139

Group type: COMPARATOR
Intervention: ILI (Intensive Lifestyle Intervention)
Number of subjects: 139
Study: 20680272

Group type: EXPERIMENTAL
Intervention: Radial head replacement
Number of subjects: 45

Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 45
Study: 19156437

Group type: EXPERIMENTAL
Intervention: Fluid intake to maintain body mass (BM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fluid intake to increase BM by 2%
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fluid intake to decrease BM by 2%
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fluid intake to decrease BM by 4%
Number of subjects: 8

Group type: COMPARATOR
Intervention: No fluid intake
Number of subjects: 8
Study: 17047639

Group type: EXPERIMENTAL
Intervention: Hypertriglyceridemic waist (HTGW) defined as waist circumference (WC) > or =90 cm and triglycerides (TG) > or =2 mmol/l
Number of subjects: 3430

Group type: COMPARATOR
Intervention: Low WC/low TG
Number of subjects: 3430

Group type: COMPARATOR
Intervention: High WC/low TG
Number of subjects: 3430

Group type: COMPARATOR
Intervention: Low WC/high TG
Number of subjects: 3430

Group type: EXPERIMENTAL
Intervention: HTGW
Number of subjects: 3430
Study: 14765138

Group type: EXPERIMENTAL
Intervention: Paravertebral repetitive magnetic stimulation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 31
Study: 12269876

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 19
Study: 10763657

Group type: EXPERIMENTAL
Intervention: Home care instruction
Number of subjects: 0
Study: 7779548

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100 micrograms daily as enriched yeast for 4 months)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 19
Study: 2157450

Group type: EXPERIMENTAL
Intervention: Guar gum (30 g/day)
Number of subjects: 9
Study: 393519

Group type: EXPERIMENTAL
Intervention: Flutonidin (0.5, 1, 2 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Clonidine (0.0075, 0.150, 0.300 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30217337

Group type: EXPERIMENTAL
Intervention: Re-irradiation with stereotactic body radiation therapy (SBRT), median BED10 of first SBRT 59.5 Gy (48-85.5 Gy), second SBRT 50.2 Gy (43.7-66.9 Gy) in training cohort; median BED10 of first SBRT 59.5 Gy (52.5-66.9 Gy), second SBRT 47.7 Gy (40.6-54.8 Gy) in validation cohort.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SCAD score < 3 points
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SCAD score ≥ 3 points
Number of subjects: 42
Study: 27179944

Group type: EXPERIMENTAL
Intervention: Active transcranial direct-current stimulation (tDCS) for ten sessions of 20 minutes at an intensity of 2 mA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham transcranial direct-current stimulation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Active transcranial direct-current stimulation (tDCS)
Number of subjects: 40
Study: 25009115

Group type: EXPERIMENTAL
Intervention: New whey-based, palm olein oil (PO)-free partially hydrolyzed formula (pHF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercially available whey-based pHF with PO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New whey-based, palm olein oil (PO)-free pHF
Number of subjects: 0
Study: 23147173

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg within 24 hours before contrast media exposure)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Control group (no atorvastatin)
Number of subjects: 410
Study: 20030684

Group type: EXPERIMENTAL
Intervention: Early steroid withdrawal (at day 5)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Late steroid withdrawal (at month 6)
Number of subjects: 96
Study: 18928685

Group type: EXPERIMENTAL
Intervention: Nebulised single dose of two 12 microg Formoterol Fumarate capsules diluted in 2.5 ml of sterile saline solution.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Three doses of Albuterol (0.15 mg/kg/dose, maximum dose 2.5 mg) every twenty minutes for one hour.
Number of subjects: 50
Study: 16108933

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2802

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 2802

Group type: EXPERIMENTAL
Intervention: Hypertension and DM
Number of subjects: 2802
Study: 11796358

Group type: EXPERIMENTAL
Intervention: Valaciclovir alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Valaciclovir with 1 g of probenecid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Valaciclovir with 800 mg of cimetidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Valaciclovir with probenecid and cimetidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Probenecid and cimetidine
Number of subjects: 12
Study: 10374166

Group type: EXPERIMENTAL
Intervention: Topical diclofenac eyedrops
Number of subjects: 16

Group type: COMPARATOR
Intervention: Topical prednisolone acetate eyedrops
Number of subjects: 16
Study: 8732700

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss program with a low-calorie diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss program with two 12-week periods of a very-low calorie diet (VLCD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss program (general)
Number of subjects: 0
Study: 1880232

Group type: EXPERIMENTAL
Intervention: Test drug (specific NSAIDs and centrally acting analgesic) administered 30 minutes before RSE.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard drugs (NSAIDs and centrally acting analgesic).
Number of subjects: 0
Study: 6313591

Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) administered intravenously at 8-hourly intervals, total daily dosage of 1500 mg/m2 for 5 days.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31985471

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 30653420

Group type: EXPERIMENTAL
Intervention: Ischemic Conditioning (IC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: IC Sham
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 29720440

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conscious sedation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 0
Study: 26670989

Group type: EXPERIMENTAL
Intervention: Inertial squat resistance exercise with eccentric overload (4 sets of 8 repetitions)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 81
Study: 25280408

Group type: EXPERIMENTAL
Intervention: Hypoxia with 8% maltodextrin (200 mL/20 min) during exercise and for 2 h after
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hypoxia after 6 d of glutamine supplementation (20 g/d) and supplementation with 8% maltodextrin (200 mL/20 min) during exercise and for 2 h after
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hypoxia with a placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hypoxia + carbohydrate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All groups (hypoxia with placebo, hypoxia with carbohydrate, hypoxia with glutamine)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Supplemented groups (hypoxia + carbohydrate + glutamine)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 9
Study: 22320409

Group type: EXPERIMENTAL
Intervention: midazolam+fentanyl and topical anesthesia
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: midazolam+fentanyl and peribulbar anesthesia
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: dexmedetomidine and topical anesthesia
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: dexmedetomidine and peribulbar anesthesia
Number of subjects: 80
Study: 21194594

Group type: COMPARATOR
Intervention: Metformin 850 mg/d
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg/d + Atorvastatin 10 mg/d
Number of subjects: 32
Study: 17490786

Group type: EXPERIMENTAL
Intervention: Prohibition of snacks (restriction of intake)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prohibition (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prohibition of snacks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very little or a lot of restriction at home
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate level of restriction at home
Number of subjects: 0
Study: 17152183

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural stress management (CBSM) intervention, 10-week duration
Number of subjects: 129

Group type: COMPARATOR
Intervention: Psychoeducational seminar group (control)
Number of subjects: 129
Study: 12119088

Group type: EXPERIMENTAL
Intervention: Subjects with brain injury
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 10339761

Group type: EXPERIMENTAL
Intervention: Inspiration Assist (IA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VC)
Number of subjects: 12
Study: 7582165

Group type: EXPERIMENTAL
Intervention: Parenteral paramethasone (Triniol)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Other corticosteroids (oral and parenteral challenges)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Skin and ELISA tests with paramethasone
Number of subjects: 2

Group type: COMPARATOR
Intervention: Prick test with excipients of paramethasone
Number of subjects: 2
Study: 1541981

Group type: EXPERIMENTAL
Intervention: rIL‐2 alone (10,000 IU/injection, escalated to 50,000 IU)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: rIL‐2 + IFN‐alpha (rIL‐2 at 10,000 IU, IFN‐alpha starting at 3 million IU escalated to 18 million IU)
Number of subjects: 9
Study: 2859274

Group type: EXPERIMENTAL
Intervention: Halazepam
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 80
Study: 31651801

Group type: EXPERIMENTAL
Intervention: IV ibuprofen (10 mg/kg, max 800 mg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 58
Study: 29747662

Group type: EXPERIMENTAL
Intervention: Progressive mobilization protocol
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 96
Study: 26253747

Group type: EXPERIMENTAL
Intervention: Telemetry-triggered interventions
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group (no telemetry support)
Number of subjects: 223
Study: 26137537

Group type: EXPERIMENTAL
Intervention: Oral artesunate (200 mg, 14 daily doses)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oral artesunate
Number of subjects: 23
Study: 23198737

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 0
Study: 21204958

Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg three times daily prior to meals
Number of subjects: 232

Group type: COMPARATOR
Intervention: Glyburide 5 mg once daily before breakfast
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 232

Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 232
Study: 18078907

Group type: EXPERIMENTAL
Intervention: Calcium acetate plus atorvastatin (Lipitor)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Sevelamer (Renagel)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Agatston score variability for cutpoints 1-30, 31-100, 101-400, and >400
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Volume score variability for cutpoints 1-30, 31-100, 101-400, and >400
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Correlation coefficient for scan A to scan B
Number of subjects: 463
Study: 16492394

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at concentrations of 5, 10, 20, and 40 parts per million (ppm) for 15 min
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 13
Study: 12890046

Group type: EXPERIMENTAL
Intervention: Low peak voltage biphasic waveform (500-microF capacitor with 40% tilt)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard biphasic waveform (60-microF capacitor with 80% tilt)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both waveforms
Number of subjects: 19
Study: 10875167

Group type: EXPERIMENTAL
Intervention: Web-based introductory psychology course
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional lecture course
Number of subjects: 0
Study: 9781939

Group type: EXPERIMENTAL
Intervention: Indapamide SR 1.5 mg
Number of subjects: 216
Study: 7942731

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day for 8 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day for 8 days
Number of subjects: 15
Study: 3220075

Group type: EXPERIMENTAL
Intervention: Glucose polymer (GP) diet supplement (230 g of GP consumed daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glucose polymer (GP) diet supplement
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (saccharin‐sweetened supplement)
Number of subjects: 15
Study: 30063554

Group type: EXPERIMENTAL
Intervention: 60-second interset rest duration
Number of subjects: 12

Group type: COMPARATOR
Intervention: 180-second interset rest duration
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Resistance exercise in hypoxia
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Resistance exercise in normoxia
Number of subjects: 12
Study: 30142833

Group type: EXPERIMENTAL
Intervention: Size 3 curved blade
Number of subjects: 221

Group type: COMPARATOR
Intervention: Size 4 curved blade
Number of subjects: 221
Study: 27926471

Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: External beam radiation therapy (EBRT) ≥40 Gy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Any kind of chemotherapy (CTX)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multimodal treatment regimen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stage-dependent overall survival (OS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Overall survival (OS) rates
Number of subjects: 100
Study: 25469044

Group type: EXPERIMENTAL
Intervention: Boceprevir-based triple therapy (PEG-IFNα2b/RBV followed by PEG-IFNα2b/RBV+Boceprevir for 32 weeks)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Boceprevir-based triple therapy
Number of subjects: 56
Study: 23122795

Group type: EXPERIMENTAL
Intervention: Chronic subcutaneous B-type natriuretic peptide (BNP) 10 μg/kg bid for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19644406

Group type: EXPERIMENTAL
Intervention: 100 mg.d(‐1) CoQ10
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 18599165

Group type: EXPERIMENTAL
Intervention: IC51 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: JE-VAX vaccine
Number of subjects: 0
Study: 15850494

Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease (COPD) smokers (stages I-III)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Asymptomatic smokers
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pack-years smoking
Number of subjects: 60
Study: 11802206

Group type: EXPERIMENTAL
Intervention: HDFL (+) in p53 (normal) group
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: HDFL (+) in p53 (overexpression) group
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: HDFL (−) in p53 (overexpression) group
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: HDFL (−) in p53 (normal) group
Number of subjects: 144

Group type: COMPARATOR
Intervention: HDFL
Number of subjects: 144
Study: 7540566

Group type: EXPERIMENTAL
Intervention: 50 IU oxytocin diluted in 10 ml 0.9% sodium chloride solution
Number of subjects: 109

Group type: COMPARATOR
Intervention: 20 ml plasma expander (dextran 70) into the umbilical vein
Number of subjects: 109
Study: 2574262

Group type: EXPERIMENTAL
Intervention: Intramuscular chloroquine (3.5 mg base/kg every 6 h)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intramuscular quinine (20 mg salt/kg followed by 10 mg/kg every 12 h)
Number of subjects: 50
Study: 5762041

Group type: EXPERIMENTAL
Intervention: (-)-hyoscine 0.4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (-)-hyoscine 0.2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (-)-hyoscine 0.1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (-)-hyoscine 0.05 mg
Number of subjects: 0
Study: 31279778

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 2100

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (LGBP)
Number of subjects: 2100
Study: 28687377

Group type: EXPERIMENTAL
Intervention: Postoperative Stereotactic Radiosurgery (SRS) - 12-20 Gy single fraction
Number of subjects: 194

Group type: COMPARATOR
Intervention: Whole Brain Radiotherapy (WBRT) - 30 Gy in ten daily fractions or 37.5 Gy in 15 daily fractions
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Postoperative Stereotactic Radiosurgery (SRS)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Whole Brain Radiotherapy (WBRT)
Number of subjects: 194
Study: 26258842

Group type: EXPERIMENTAL
Intervention: ABA training combined with oral bumetanide (0.5 mg twice a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ABA training only
Number of subjects: 60